Tag Archives: Boehringer Ingelheim

Highmark’s Strategy to Contain Drug Costs Includes an Increasing Number of Outcome-Based Contracts

Pharmaceutical manufacturers and payers have developed a number of agreements under which reimbursement is contingent on specific outcomes over the last few years

Highmark Develops Initiatives to Control Drug Spending

Highmark members will receive hemophilia drugs exclusively from three specialty pharmacies

Medisafe Increasing Pharma Partnerships

Digital therapeutic and pharmaceutical companies continue to determine how to integrate their resources to collaborate successfully